title: Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129.
abstract: BACKGROUND
  This report focuses on the children enrolled on the first North American Intergroup study of APL (INT0129). This study was designed to compare the rates of CR, disease-free survival (DFS), overall survival (OS) and toxicity of therapy with all-trans-retinoic acid (ATRA) for remission induction and/or maintenance compared to conventional chemotherapy in patients with previously untreated APL.
  
  
  METHODS
  Fifty-three patients who were documented to have the t(15;17) translocation were able to be evaluated for toxicity of treatment, outcome of induction, and survival.
  
  
  RESULTS
  The overall CR rate was 81%. The estimated 5-year DFS from time of CR was 41% for all patients. The estimated 5-year OS for all patients from entry into the study was 69%. The 5-year DFS from time of CR for patients who were randomized to ATRA for induction or maintenance or both was 48% compared to 0% for patients who never received ATRA (P < 0.0001).
  
  
  CONCLUSIONS
  The most important finding of our study is that a significant DFS advantage exists for children with APL who received ATRA during induction or maintenance or both compared to children who received no ATRA. Furthermore, remissions in these children appear durable as the OS rates are stable at 10 years.
authors.affiliation: Morristown Memorial Hospital, Morristown, New Jersey 07962, USA. john.gregoryjr@atlantichealth.org
authors.forename: John
authors.initials: J
authors.lastname: Gregory
authors.forename: Haesook
authors.initials: H
authors.lastname: Kim
authors.forename: Todd
authors.initials: T
authors.lastname: Alonzo
authors.forename: Rob
authors.initials: R
authors.lastname: Gerbing
authors.forename: William
authors.initials: W
authors.lastname: Woods
authors.forename: Howard
authors.initials: H
authors.lastname: Weinstein
authors.forename: Lois
authors.initials: L
authors.lastname: Shepherd
authors.forename: Charles
authors.initials: C
authors.lastname: Schiffer
authors.forename: Frederick
authors.initials: F
authors.lastname: Appelbaum
authors.forename: Cheryl
authors.initials: C
authors.lastname: Willman
authors.forename: Peter
authors.initials: P
authors.lastname: Wiernik
authors.forename: Jacob
authors.initials: J
authors.lastname: Rowe
authors.forename: Martin
authors.initials: M
authors.lastname: Tallman
authors.forename: James
authors.initials: J
authors.lastname: Feusner
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012074:Remission Induction / Q000379:methods; D016019:Survival Analysis; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage* / Q000633:toxicity
chemical_list: D003561:Cytarabine; D014212:Tretinoin; D003630:Daunorubicin